News | January 27, 2015

Ortho-Clinical Diagnostics Introduces Test to Assess Risk for Acute Kidney Injury

Early knowledge of AKI risk may prompt closer patient monitoring and help prevent permanent kidney damage or death

Nephrocheck Test System, Blood testing, contrast media

Image courtesy of Astute Medical

January 27, 2015 — Ortho-Clinical Diagnostics Inc. announced the nationwide availability to hospitals of the Nephrocheck Test System designed to help healthcare providers identify patients at risk of developing moderate or severe acute kidney injury (AKI) within 12 hours of patient assessment.

In comparing patients with AKI to patients without AKI, hospital and the intensive care unit lengths of stay double, as do costs of care and readmission rates.  Death rates at one year are higher among patients with AKI alone, compared to those patients with heart attack alone.

AKI usually lacks signs and symptoms and can potentially result in irreversible kidney damage if recognition is delayed. In clinical studies, the Nephrocheck Test identified the majority of patients that developed moderate to severe AKI within 12 hours of assessment.

The Nephrocheck Test result, called the AKIRisk Score, has the ability to distinguish patients with AKI from those without AKI. Based on results from clinical studies, patients with a positive AKIRisk Score (greater than the cutoff of 0.3) have a one in four to a one in three chance of developing moderate or severe AKI within 12 hours of assessment.

To calculate the AKIRisk Score, the Nephrocheck Test System measures the concentrations of two urinary biomarkers using the Astute140 Meter. The two novel biomarkers -- tissue inhibitor of metalloproteinase 2 and insulin-like growth factor binding protein 7, are thought to be involved in G1 cell cycle arrest in the earliest phases of injury.

In July 2014, Ortho-Clinical Diagnostics entered into collaboration with Astute Medical Inc., the developer of the Nephrocheck Test System, to become the exclusive sales agent for Astute Medical’s Nephrocheck Test and the Astute140 Meter in the United States and in certain countries of the European Union.

For more information: www.orthoclinical.com/en-us/Pages/Home.aspx, www.astutemedical.com

 

 

Related Content

Bayer Introduces Medrad Stellant Flex CT Injection System
Technology | Contrast Media Injectors | September 11, 2019
Bayer announced the introduction of the Medrad Stellant Flex computed tomography (CT) injection system. Stellant Flex...
Characteristics nephrologists associate with renal high-risk patients. (n=13)

Characteristics nephrologists associate with renal high-risk patients. (n=13)

Feature | Contrast Media | September 05, 2019
The global rise in chronic disease has significantly increased demand for diagnostic imaging procedures, and in turn,
News | Contrast Media | September 03, 2019
Researchers in South Korea have found that patients with family and personal history of allergic reactions to contrast...
Displacement comparison at the end-systolic frame and final frame

Displacement comparison at the end-systolic frame and final frame. The three patients (V6, V10, V16) with different left-ventricle walls are shown. Point-to-surface distance is a measure to estimate the distance of a point from the reference surface. Image courtesy of WMG, University of Warwick

News | Cardiac Imaging | August 28, 2019
A new 3-D magnetic resonance imaging (MRI) computing technique developed by scientists in WMG at the University of...
Some Pregnant Women Are Exposed to Gadolinium in Early Pregnancy
News | Women's Health | August 20, 2019
A small but concerning number of women are exposed to a commonly used magnetic resonance imaging (MRI) contrast agent...
Contrast Use in First Transthoracic Echocardiogram for Heart Failure Reduces Repeat Testing
News | Cardiovascular Ultrasound | August 07, 2019
Heart failure is the fourth most common cause for all admission to U.S. hospitals, and it is the most common reason for...
Bracco Receives FDA Approval for Varibar Thin Liquid for Oral Suspension
Technology | Contrast Media | August 05, 2019
Bracco Diagnostics Inc. announced U.S. Food and Drug Administration (FDA) approval for Varibar Thin Liquid (barium...
Two brain metastases from primary lung cancer are contrast enhanced in the brain of a 61-year-old male. Speakers at AHRA 2019 will state that ProHance and other macrocyclic MR agents present a very low risk to patients. Images courtesy of Bracco

Two brain metastases from primary lung cancer are contrast enhanced in the brain of a 61-year-old male. Speakers at AHRA 2019 will state that ProHance and other macrocyclic MR agents present a very low risk to patients. Images courtesy of Bracco

Feature | Contrast Media | July 18, 2019 | By Greg Freiherr
Macrocyclic contrast agents have the best safety profile of all the magnetic resonance (MR) contrast media that are n
FDA Approves Bayer's Gadavist Contrast for Cardiac MRI in Adult Coronary Artery Disease Patients
Technology | Contrast Media | July 15, 2019
The U.S. Food and Drug Administration (FDA) has approved Gadavist injection for use in cardiac magnetic resonance...
ITN Wins Jesse H. Neal Award for Best Technical Content
News | Radiology Business | April 24, 2019
April 24, 2019 — Imaging Technology News (ITN) was recently named the 2019 Jesse H.